Alectinib (Alecensa©) as monotherapy for the first line treatment of adult patients with ALK-positive advanced non-small cell lung cancer (NSCLC)
This is the assessment of the relative effectiveness of “Alectinib (Alecensa©) as monotherapy for the first line treatment of adult patients with ALK-positive advanced non-small cell lung cancer (NSCLC)”. The final version of the assessment was published in January 2018. Below is the documentation provided by the Joint Assessment authoring team: PTJA03 Alectinib Final Assessment […]
Transcatheter aortic valve implantation (TAVI) in patients at intermediate surgical risk
This is the final project plan of the Other Technologies CA on Transcatheter aortic valve implantation (TAVI) in patients at intermediate surgical risk. (FINAL) Project Plan WP4 CA (TAVI)
The CA of JA3 WP4 on “Repetitive transcranial magnetic stimulation for treatment-resistant major depression” is now available.
We are pleased to announce that the CA of JA3 WP4 on “Repetitive transcranial magnetic stimulation for treatment-resistant major depression” is available. The purpose of the assessment is to examine the effectiveness and safety of repetitive transcranial magnetic stimulation (rTMS) in adult patients with treatment-resistant major depression. The analysis included CE-marked rTMS devices. Final version […]
The CA of JA3 WP4 on “Antibacterial-coated Sutures Versus Non-Antibacterial-Coated Sutures for the Prevention of Abdominal, Superficial and Deep Incisional, Surgical Site Infection (SSI)” is now available.
We are pleased to announce that the collaborative rapid assessment of JA3 WP4 on “ANTIBACTERIAL-COATED SUTURES VERSUS NON-ANTIBACTERIAL-COATED SUTURES FOR THE PREVENTION OF ABDOMINAL, SUPERFICIAL AND DEEP INCISIONAL, SURGICAL SITE INFECTION (SSI)” is available. Surgical site infection (SSI) is a frequent type of nosocomial infection, accounting for about 14% to 15% of the total number […]
Screening of Fetal Aneuplodies Whereby Non-invasive Prenatal Test (NIPT)
This is the final project plan of the CA on “Screening of fetal aneuplodies whereby non-invasive prenatal test (NIPT)”. Included are the external comments on the project plan, including the authors’ answers to the comments. Project Plan_OTCA03_external comments Project_Plan_OTCA03_Aneuplodies screening by NIPT_ FINAL
Regorafenib (Stivarga©) indicated as monotherapy for the treatment of adult patients with hepatocellular carcinoma (HCC) who have been previously treated with sorafenib
Final Assessment Report, External Comments/Answers and Project Plan for pharma JA on Regorafenib (Stivarga©) The purpose of the assessment is to evaluate Regorafenib (Stivarga©) indicated as monotherapy for the treatment of adult patients with hepatocellular carcinoma (HCC) who have been previously treated with sorafenib. Final version of the assessment was published in October 2017. Below […]
MammaPrint® – Added value of using gene-expression signature for adjuvant chemotherapy decisions in early breast cancer assessment
This is the final project plan of the Other Technologies CA on MammaPrint® – Added value of using gene-expression signature for adjuvant chemotherapy decisions in early breast cancer assessment (OTCA04) EUnetHTA_Project_Plan_OTCA04_version_final_without_appendix(1)
Final assessment report on midostaurin (Rydapt©) in combination with standard daunorubicin and cytarabine induction and high-dose cytarabine consolidation chemotherapy
Final Assessment Report, External Comments/Answers and Project Plan for pharma JA on midostaurin (Rydapt©) This is the assessment of the relative effectiveness of midostaurin (Rydapt©) in combination with standard daunorubicin and cytarabine induction and high-dose cytarabine consolidation chemotherapy for patients in complete response, followed by midostaurin monotherapy for adult patients with newly diagnosed acute myeloid […]
EMA-EUnetHTA Parallel Consultation
Parallel consultation between EUnetHTA and the European Medicines Agency As of July 2017, EUnetHTA and the European Medicines Agency (EMA) offer parallel consultations on evidence generation plans. This aims to allow medicine developers to obtain feedback from regulators and health technology assessment (HTA) bodies on their development plans to support decision-making on marketing authorisation, health […]
EMA-EUnetHTA meeting June 2017 – Final minutes
20170608 – EMA-EUnetHTA Meeting Minutes – FINAL
